Award of cytosorbents' DHA sttr RIF phase III medical r & d contract from proposal DHP15B-001-p-6144 for "development of a highly efficient adsorber to remove anti-a and anti-b antibodies from blood…
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0050
- Awardee
-
Cytosorbents Medical Inc. UEI LSF2KFUSY4K7 Part of Cytosorbents Corporation
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $2,897,172
Award facts
- Contract value 100% obligated
- $2,897,172.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AN91 R&D- Medical: Other (Basic Research)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Monmouth Junction, South Brunswick Township, NJ 08852, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,897,172 |
About this award
The Defense Health Agency awarded a $2.9 million firm fixed-price Phase III Small Business Technology Transfer Research (STTR) contract to Cytosorbents Medical Inc. on June 15, 2020, for the development of a highly efficient adsorber to remove anti-A and anti-B antibodies from blood and plasma for transfusion applications. The contract, designated as a total small business set-aside, is scheduled for completion by October 14, 2023, with performance taking place at the contractor's facility in Monmouth Junction, New Jersey. This Phase III award represents the final stage of the STTR program, intended to commercialize technologies developed during earlier research phases and transition them toward operational deployment or market viability.
Cytosorbents Medical's blood purification technology aligns with the Defense Health Agency's interest in advancing critical care medical capabilities. The company's work on blood group antibody removal supports the strategic objective of enabling more flexible transfusion capabilities, particularly valuable in military medical operations and trauma scenarios where blood type matching constraints typically limit donor availability. As a small business receiving a set-aside contract award, Cytosorbents has also secured complementary funding from the National Institutes of Health and Department of the Army to advance related blood purification technologies, demonstrating sustained federal investment in the contractor's medical device innovation pipeline.
Description
Award of cytosorbents' DHA sttr RIF phase III medical r & d contract from proposal DHP15B-001-p-6144 for "development of a highly efficient adsorber to remove anti-a and anti-b antibodies from blood and plasma for transfusion"
Quick answers
Who was awarded contract W81XWH20C0050?
W81XWH20C0050 was awarded to Cytosorbents Medical Inc. by Medical Command (Department of the Army) on June 15, 2020.
How much is contract W81XWH20C0050 worth?
The government has obligated $2,897,172 on W81XWH20C0050.
Was contract W81XWH20C0050 competed?
The extent of competition for W81XWH20C0050 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award